LTA TAlternative Names: Lipoteichoic acid - LUNAMeD AG; oncomycin
Latest Information Update: 21 Sep 2015
At a glance
- Originator LUNAMeD AG
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Malignant ascites; Pleural effusion
Most Recent Events
- 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pleural effusion in Europe (SC)
- 21 Sep 2015 No recent reports on development identified - Phase-I/II for Malignant ascites in Europe (SC)
- 21 Sep 2015 No recent reports on development identified - Phase-I for Cancer in Europe (SC)